The General Hospital Corporation

United States of America

Back to Profile

1-100 of 307 for The General Hospital Corporation Sort by
Query
Patent
Canada - CIPO
Excluding Subsidiaries
Aggregations Reset Report
Date
2023 7
2022 29
2021 22
2020 31
2019 24
See more
IPC Class
A61P 35/00 - Antineoplastic agents 29
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia 24
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum 22
C07K 19/00 - Hybrid peptides 20
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants 18
See more
Status
Pending 191
Registered / In Force 116
Found results for  patents
  1     2     3     4        Next Page

1.

CRISPR-ASSOCIATED TRANSPOSASES AND METHODS OF USE THEREOF

      
Document Number 03241474
Status Pending
Filing Date 2022-12-02
Open to Public Date 2023-06-08
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Kleinstiver, Benjamin
  • Tou, Connor J.

Abstract

Described herein are improved CRISPR-associated transposases (CASTs), including homing endonuclease-assisted large-sequence integrating CRISPR-associated transposases (CAST) complexes and methods of use thereof, and other strategies to improve the activities of natural and engineered CASTs.

IPC Classes  ?

  • C07K 19/00 - Hybrid peptides
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • C07K 14/195 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 9/22 - Ribonucleases
  • C12N 15/62 - DNA sequences coding for fusion proteins
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

2.

SYSTEM AND METHOD FOR INTRAOPERATIVE LIFETIME IMAGING

      
Document Number 03236899
Status Pending
Filing Date 2022-10-25
Open to Public Date 2023-05-04
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Kumar, Anand T.N.
  • Pal, Rahul
  • Krishnamoorthy, Murali

Abstract

A method and system for assessing tissue to determine a presence or absence of cancer cells. The method includes acquiring fluorescence lifetime (FLT) data from tissue and processing the FLT data to determine a FLT signal at each of a plurality of locations across the tissue. The method also includes determining FLT data at any of the plurality of locations above a threshold indicative a presence of cancer cells and generating a report indicating any of the plurality of locations above the threshold as indicative the presence of cancer cells.

IPC Classes  ?

  • G01N 21/64 - Fluorescence; Phosphorescence
  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
  • G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
  • G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

3.

IMPROVED CRISPR PRIME EDITORS

      
Document Number 03234834
Status Pending
Filing Date 2022-10-07
Open to Public Date 2023-04-13
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Joung, J. Keith
  • Grunewald, Julian
  • Miller, Bret

Abstract

Described herein are split and reduced size CRISPR Prime Editors, as well as variant reverse transcriptases, and methods of use thereof.

IPC Classes  ?

  • C12N 9/22 - Ribonucleases
  • C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

4.

COMPOSITIONS AND METHODS FOR ENHANCING WNT SIGNALING FOR TREATING CANCER

      
Document Number 03233974
Status Pending
Filing Date 2022-10-07
Open to Public Date 2023-04-13
Owner
  • MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Eng, George
  • Yilmaz, Omer
  • Braverman, Jonathan

Abstract

Methods and compositions for enhancing Wnt signaling pathway activities in a tissue of a subject have been developed for the treatment of cancer, in particular cancers with one or more mutations in the APC (adenomatous polyposis coli) gene. Preferably, the amount of the compositions for enhancing Wnt signaling does not reduce or inhibit proliferation or viability of normal healthy cells in the subject. In some embodiments, pharmaceutical compositions including an effective amount of one or more GSK-3 inhibitors are administered to reduce cancer cell proliferation or viability in a subject. A preferred GSK-3 inhibitor is LY2090314 encapsulated within, or associated with nanoparticles. Dosage forms of LY2090314 encapsulated within, or associated with nanoparticles for administration are also described.

IPC Classes  ?

  • A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
  • A61P 35/00 - Antineoplastic agents

5.

METHODS FOR IDENTIFYING CROSS-MODAL FEATURES FROM SPATIALLY RESOLVED DATA SETS

      
Document Number 03230265
Status Pending
Filing Date 2022-03-10
Open to Public Date 2023-03-09
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Sirbulescu, Ruxandra F.
  • Hess, Josh
  • Reeves, Patrick M.
  • Poznansky, Mark C.

Abstract

Disclosed are methods of identifying a cross-modal feature from two or more spatially resolved data sets, the method including: (a) registering the two or more spatially resolved data sets to produce an aligned feature image including the spatially aligned two or more spatially resolved data sets; and (b) extracting the cross-modal feature from the aligned feature image.

IPC Classes  ?

  • G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
  • G06T 7/33 - Determination of transform parameters for the alignment of images, i.e. image registration using feature-based methods
  • G06V 10/762 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using clustering, e.g. of similar faces in social networks
  • G06T 7/00 - Image analysis

6.

INHIBITORS OF 12/15-LIPOXYGENASE

      
Document Number 03228721
Status Pending
Filing Date 2022-08-05
Open to Public Date 2023-02-16
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Van Leyen, Klaus
  • Zheng, Yi
  • Holman, Theodore
  • Johnson, Graham
  • Herr, Robert Jason

Abstract

The present application provides oxazoles-containing compounds, or a pharmaceutically acceptable salt thereof, that are 12/15-LOX inhibitors. Pharmaceutical compositions and methods of using these compounds for treating various conditions wherein 12/15-LOX is implicated (such as stroke) are also provided.

IPC Classes  ?

  • C07D 263/48 - Nitrogen atoms not forming part of a nitro radical
  • A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
  • A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
  • A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
  • A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
  • A61K 31/501 - Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
  • A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
  • C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07F 9/653 - Five-membered rings

7.

BIFIDOBACTERIUM LONGUM TRANSITIONAL MICROORGANISMS, COMPOSITIONS AND USES THEREOF

      
Document Number 03223920
Status Pending
Filing Date 2022-06-28
Open to Public Date 2023-01-05
Owner
  • THE BROAD INSTITUTE, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • SOCIETE DES PRODUITS NESTLE, S.A. (Switzerland)
Inventor
  • Xavier, Ramnik
  • Vlamakis, Hera
  • Vatanen, Tommi
  • Sakwinska, Olga
  • Siegwald, Lea
  • Duboux, Stephane
  • Ngom-Bru, Catherine

Abstract

Described in several exemplary embodiments are Bifidobacterium longum subspecies, microorganisms and formulations thereof. Described in several exemplary embodiments are formulations, such as synthetic formulations, that contain one or more of the Bifidobacterium longum subspecies microorganisms. Described in several embodiments herein is use of the Bifidobacterium longum subspecies microorganisms and formulations thereof, such as in an infant and/or young child.

IPC Classes  ?

  • A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics

8.

ERK1/2 INHIBITOR COMBINATION THERAPY

      
Document Number 03223692
Status Pending
Filing Date 2022-06-23
Open to Public Date 2022-12-29
Owner
  • ASANA BIOSCIENCES, LLC (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Gupta, Sandeep
  • Denis, Louis
  • Reddy, Sanjeeva
  • Corcoran, Ryan B.

Abstract

The present invention relates generally to the use of an ERK1/2 inhibitor in combination with a B-Raf inhibitor that is encorafenib or dabrafenib for treating cancer, specifically solid tumors.

IPC Classes  ?

  • A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61P 35/00 - Antineoplastic agents

9.

COMPOSITIONS AND METHODS FOR LARGE-SCALE IN VIVO GENETIC SCREENING

      
Document Number 03222127
Status Pending
Filing Date 2022-06-08
Open to Public Date 2022-12-15
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • UNIVERSITY OF UTAH RESEARCH FOUNDATION (USA)
Inventor
  • Yeh, Jing-Ruey Joanna
  • Parvez, Saba
  • Peterson, Randall T.

Abstract

Disclosed herein are droplets comprising gene editing systems and barcodes. The disclosure further relates to methods for large-scale identification of genes in vivo using barcodes and methods for large-scale identification of gene function in a plurality of subjects using a plurality of droplets.

IPC Classes  ?

  • C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection

10.

INHIBITORS OF TTBK1

      
Document Number 03222586
Status Pending
Filing Date 2022-06-07
Open to Public Date 2022-12-15
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • DANA-FARBER CANCER INSTITUTE, INC. (USA)
Inventor
  • Haggarty, Stephen John
  • Da Silva, Maria Catarina Telo Baptista Lima
  • Ferguson, Fleur Marcia
  • Gray, Nathaniel S.

Abstract

The present application provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising the compound of Formula (I), and methods of using said compound and said compositions for treating neurodegenerative diseases, are also provided.

IPC Classes  ?

  • A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
  • A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 47/08 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 487/04 - Ortho-condensed systems

11.

MOLECULAR PROBES FOR IN VIVO DETECTION OF ALDEHYDES

      
Document Number 03220010
Status Pending
Filing Date 2022-05-13
Open to Public Date 2022-11-17
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Caravan, Peter
  • Ning, Yingying
  • Ma, Hua
  • Shuvaev, Sergey
  • Akam, Eman

Abstract

Disclosed herein are methods of molecular magnetic resonance (MR) imaging and positron emission tomography using extracellular probes that target extracellular allysine aldehyde and act as a noninvasive biomarker of fibrogenesis with high sensitivity and specificity in detecting fibrogenesis, for example, in rodent models and human fibrotic tissues.

IPC Classes  ?

  • C07D 255/02 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups not condensed with other rings
  • A61K 49/06 - Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations
  • C07D 257/02 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings

12.

ANIMAL MODEL HAVING HOMOLOGOUS RECOMBINATION OF MOUSE PTH1 RECEPTOR

      
Document Number 03217862
Status Pending
Filing Date 2022-05-05
Open to Public Date 2022-11-10
Owner
  • RADIUS PHARMACEUTICALS, INC. (USA)
  • THE GENERAL HOSPITAL CORPOATION (USA)
Inventor
  • Mannstadt, Beate Klara Maria
  • Gardella, Thomas James

Abstract

New transgenic non-human animals comprising human Parathyroid Hormone 1 Receptor (hPTHIR), and methods of producing the same; new assays and screening techniques to evaluate the hPTHIR; and methods and transgenic animals to evaluate the response of hPTHIR to one or more candidate agents.

IPC Classes  ?

  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C07K 14/72 - Receptors; Cell surface antigens; Cell surface determinants for hormones
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 15/09 - Recombinant DNA-technology
  • C12N 15/12 - Genes encoding animal proteins
  • C12N 15/90 - Stable introduction of foreign DNA into chromosome
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • A01K 67/0275 - Genetically modified vertebrates, e.g. transgenic

13.

AAV CAPSIDS AND USES THEREOF

      
Document Number 03218071
Status Pending
Filing Date 2022-04-27
Open to Public Date 2022-11-03
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Musolino, Patricia L.
  • Maguire, Casey A.
  • Hudry, Eloise
  • Hanlon, Killian S.

Abstract

Described herein are capsid peptides that mediated efficient AAV transduction of the brain vasculature, mainly endothelial cells and pericytes, as well as smooth muscle cells, compositions (including AAV), and methods of using the same. Embodiments of the invention encompass AAV capsid proteins comprising an amino acid sequence that comprises at least four, at least five, or at least six contiguous amino acids from the sequence PRPPSTH (SEQ ID NO: 1); MAEPGAR (SEQ ID NO: 2); SQDPSTL (SEQ ID NO: 3); or MLYADNT (SEQ ID NO: 4).

IPC Classes  ?

14.

WS635 USES THEREOF IN MEDICINE

      
Document Number 03214087
Status Pending
Filing Date 2021-04-09
Open to Public Date 2022-10-13
Owner
  • WATERSTONE PHARMACEUTICALS (WUHAN) CO., LTD. (China)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Zhang, Faming
  • Shen, Yuan
  • Cui, Jian
  • Yu, Yao
  • Hu, Minglong
  • Xie, Zhongcong

Abstract

Use of the compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof in the manufacture of a medicament or pharmaceutical composition for preventing, treating or lessening Postoperative Delirium (POD).

IPC Classes  ?

  • A61K 38/13 - Cyclosporins
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

15.

SYSTEMS AND METHODS FOR INCREASING METABOLIC RATES

      
Document Number 03216367
Status Pending
Filing Date 2022-04-11
Open to Public Date 2022-10-13
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Manstein, Dieter
  • Wang-Evers, Michael
  • Salma, Nunciada

Abstract

A treatment system can include an energy source configured to thermally damage skin tissue of a subject, a user input device configured to receive a user input, and a computing device that can be configured to receive, from the user input device, the user input indicative of one or more operational parameters of the energy source based on the user input, control the energy source according to the one or more operational parameters to cause the energy source to thermally damage the skin tissue by creating a plurality of treatment regions within a target region of the skin tissue to increase a basal metabolic rate of the subject, wherein the target region includes a non-treatment portion that is interspersed among the treatment regions.

IPC Classes  ?

  • A61N 1/02 - Electrotherapy; Circuits therefor - Details

16.

METHODS FOR INHIBITING RAS

      
Document Number 03214155
Status Pending
Filing Date 2022-04-01
Open to Public Date 2022-10-06
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • REVOLUTION MEDICINES, INC. (USA)
Inventor
  • Corcoran, Ryan B.
  • Nichols, Robert J.

Abstract

The disclosure features methods for inhibiting RAS proteins, e.g., RAS proteins that have acquired resistance to one or more RAS inhibitors. The disclosure also methods for the treatment of cancer.

IPC Classes  ?

  • C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

17.

COMPOSITIONS AND METHODS FOR PREVENTING OR DELAYING PUBERTY IN PREPUBESCENT NON-HUMAN ANIMALS AND HUMANS

      
Document Number 03212779
Status Pending
Filing Date 2022-03-22
Open to Public Date 2022-09-29
Owner THE GENERAL HOSPITAL CORPOATION (USA)
Inventor
  • Donahoe, Patricia K.
  • Pepin, David

Abstract

The present invention relates to compositions and methods of reducing fertility and/or preventing puberty in prepubescent non-human subjects (e.g., kittens and puppies) by administering a composition comprising a vector comprising a nucleic acid encoding a Mullerian Inhibiting Substance (MIS) operatively linked to one or more regulatory elements. In some embodiments, administration is via a single or multiple injection. Other aspects relate to method and compositions for delaying puberty in a human female subject by administering a recombinant human MIS variant protein.

IPC Classes  ?

  • C12N 15/16 - Hormones
  • A61K 38/22 - Hormones
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61P 15/18 - Feminine contraceptives
  • C07K 14/575 - Hormones
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N 15/86 - Viral vectors

18.

HUMANIZED MAB107

      
Document Number 03214962
Status Pending
Filing Date 2022-03-25
Open to Public Date 2022-09-29
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Arnaout, M. Amin

Abstract

Described herein are humanized antibodies that bind to Leukocyte integrin CD11b/CD18 (CD11b, aMß2, CR3) with enhanced affinity, and methods of use thereof.

IPC Classes  ?

  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

19.

METHODS FOR TREATING AUTISM SPECTRUM DISORDER

      
Document Number 03210513
Status Pending
Filing Date 2022-02-02
Open to Public Date 2022-08-11
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Joshi, Gagan

Abstract

Described herein are methods for predicting treatment response to glutamate modulating agents, selecting treatment comprising glutamate modulating agents, for, and treating subjects with glutamate modulating agents, in subjects with autism spectrum disorder (ASD).

IPC Classes  ?

  • A61K 31/13 - Amines, e.g. amantadine
  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61P 25/22 - Anxiolytics
  • A61P 25/24 - Antidepressants
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 43/00 - Drugs for specific purposes, not provided for in groups
  • G01N 33/15 - Medicinal preparations

20.

METHODS AND COMPOSITIONS FOR INCREASING THE CONCENTRATION OF CELL FREE DNA

      
Document Number 03209121
Status Pending
Filing Date 2022-01-25
Open to Public Date 2022-07-28
Owner
  • THE BROAD INSTITUTE, INC. (USA)
  • MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Love, J. Christopher
  • Martin, Alonso Maria Carmen
  • Bhatia, Sangeeta N.
  • Tabrizi, Shervin
  • Adalsteinsson, Viktor A.
  • Xiong, Kan

Abstract

This disclosure provides a method for substantially increasing the concentration of cfDNA in a patient. By injecting a patient with lipid and/or polymer nanoparticles, agents that bind cfDNA, or inhibit deoxyribonucleases prior to collection of a sample of cfDNA, e.g., by way of a liquid biopsy, major pathways for the degradation of cfDNA are temporarily blocked, permitting transient accumulation of cfDNA. This strategy has the potential to dramatically enhance the quality of detection achieved by downstream cfDNA analytical applications, such as sequencing applications.

IPC Classes  ?

  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
  • C12Q 1/6825 - Nucleic acid detection involving sensors
  • C08L 101/12 - Compositions of unspecified macromolecular compounds characterised by physical features, e.g. anisotropy, viscosity or electrical conductivity
  • G01N 33/551 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic

21.

PROBIOTICS COMPOSITIONS AND METHOD OF USING THE SAME TO ENHANCE GROWTH AND SOCIAL FUNCTION IN CHILDREN

      
Document Number 03205469
Status Pending
Filing Date 2021-12-17
Open to Public Date 2022-06-23
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Kong, Xue-Jun

Abstract

Disclosed herein are methods and compositions useful for the treatment of subjects suffering from Prader-Willi Syndrome (PWS). The methods include administering compositions comprising probiotics, such as Lactobacillus reuteri (L. reuteri) and Bifidobacterium animalis subsp. lactis (B. Lactis) to subjects in need thereof.

IPC Classes  ?

22.

METHODS OF USING INTERLEUKIN-2 AGENTS

      
Document Number 03203977
Status Pending
Filing Date 2021-12-03
Open to Public Date 2022-06-09
Owner
  • VISTERRA, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Shriver, Zachary
  • Ramakrishnan, Boopathy
  • Babcock, Gregory
  • De Jesus Borges, Thiago
  • Riella, Leonardo Vidal
  • Carlson, Scott Moore

Abstract

IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.

IPC Classes  ?

23.

METHODS FOR CHARACTERIZING BIOLOGICAL SAMPLES

      
Document Number 03200667
Status Pending
Filing Date 2021-11-05
Open to Public Date 2022-05-12
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • THE HOSPITAL FOR SICK CHILDREN (Canada)
Inventor
  • Getz, Gad
  • Maruvka, Yosef
  • Tabori, Uri
  • Chung, Jiil

Abstract

The disclosure features in some aspects methods for identifying subjects with constitutional mismatch repair deficiency (CMMRD), a mismatch repair deficiency (MMD) cancer, a polymerase proofreading deficiency (PPD) cancer, and/or a MMD&PPD cancer. The disclosure also features in some aspects methods for predicting response of a subject to immunotherapy.

IPC Classes  ?

  • C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
  • C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

24.

COMPOSITIONS AND METHODS FOR TUMOR CHARACTERIZATION

      
Document Number 03200666
Status Pending
Filing Date 2021-11-05
Open to Public Date 2022-05-12
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Getz, Gad
  • Maruvka, Yosef

Abstract

The invention provides methods for characterizing microsatellite instability in biological samples and for selecting a treatment for a subject having a neoplasia.

IPC Classes  ?

  • C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

25.

BIFUNCTIONAL COMPOUNDS AND METHODS OF USING THE SAME

      
Document Number 03201418
Status Pending
Filing Date 2021-11-05
Open to Public Date 2022-05-12
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Kurnick, James T.
  • Dunn, Ian Seymour
  • Lawler, Matthew M.

Abstract

The present disclosure provides bifunctional compounds and methods of labeling a cell having an azide-modified sugar on its surface by contacting the cell with a bifunctional compound.

IPC Classes  ?

  • A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K 49/00 - Preparations for testing in vivo
  • C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

26.

KITS, REAGENTS AND METHODS FOR THE ASSESSMENT OF LIVER DISEASES

      
Document Number 03196736
Status Pending
Filing Date 2021-10-26
Open to Public Date 2022-05-05
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Grinspoon, Steven K.

Abstract

The present application relates to methods, reagents and kits for the assessment of the severity of nonalcoholic fatty liver disease (NAFLD) in a patient over time, and/or of the likelihood that a subject suffers from NAFLD. The methods, reagents and kits are based on the determination of the levels of VEGFA, TGFB1, and/or CSF1 in a biological sample, such as a plasma sample, from the subject. The methods, reagents and kits may be used, for example, for assessing the progression of NAFLD in a patient and/or the response of the patient to therapy.

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • G01N 33/48 - Biological material, e.g. blood, urine; Haemocytometers
  • G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

27.

METHODS AND SYSTEMS FOR STRATIFYING INFLAMMATORY BOWEL DISEASE PATIENTS

      
Document Number 03194324
Status Pending
Filing Date 2021-10-05
Open to Public Date 2022-04-14
Owner
  • CEDARS-SINAI MEDICAL CENTER (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • THE BROAD INSTITUTE, INC. (USA)
Inventor
  • Mcgovern, Dermot
  • Li, Dalin
  • Huang, Hailiang
  • Liu, Ruize
  • Ruan, Yunfeng
  • Daly, Mark

Abstract

Provided herein are methods, compositions and kits for use in identifying a subject with inflammatory bowel disease.

IPC Classes  ?

  • C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
  • G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
  • G16H 70/60 - ICT specially adapted for the handling or processing of medical references relating to pathologies
  • G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
  • G16B 40/00 - ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

28.

BCG VACCINATIONS FOR PREVENTION OF COVID-19 AND OTHER INFECTIOUS DISEASES

      
Document Number 03196596
Status Pending
Filing Date 2021-09-23
Open to Public Date 2022-03-31
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Faustman, Denise L.

Abstract

The invention relates, in part, to a method for the prophylactic treatment of a coronavirus infection in a human adult subject comprising administering at least two doses of a Bacillus Calmette-Guerin (BCG) vaccine to the subject, wherein the subject is a type I diabetic.

IPC Classes  ?

  • A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
  • A61P 31/06 - Antibacterial agents for tuberculosis
  • A61P 37/04 - Immunostimulants
  • C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus

29.

AUTOMATED ANEUPLOIDY SCREENING USING ARBITRATED ENSEMBLES

      
Document Number 03192444
Status Pending
Filing Date 2021-09-13
Open to Public Date 2022-03-17
Owner
  • THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
  • THE GENERAL HOSPITAL CORPOATION (USA)
Inventor
  • Shafiee, Hadi
  • Bormann, Charles
  • Kanakasabapathy, Manoj Kumar
  • Thirumalaraju, Prudhvi

Abstract

Systems and methods are provided for fully automated screening for aneuploidy in a human embryo. An image of the embryo is obtained at an associated imager and provided to a neural network to generate a first clinical parameter. A set of at least one parameter representing one of biometric parameters of one of a patient receiving the embryo, an egg utilized to produce the human embryo, a sperm used to create the embryo, a sperm donor who provided sperm used to create the embryo, and an egg donor who provided the egg is retrieved, and a second clinical parameter is generated from the set of at least one parameter at a predictive model. A composite parameter, representing a likelihood of aneuploidy in the embryo, is generated from the first clinical parameter and the second clinical parameter.

IPC Classes  ?

  • G16B 20/10 - Ploidy or copy number detection
  • G16B 40/00 - ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
  • G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
  • G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C40B 60/12 - Apparatus specially adapted for use in combinatorial chemistry or with libraries for screening libraries
  • G06T 7/00 - Image analysis

30.

DETERMINING LOCATIONS IN REPRODUCTIVE CELLULAR STRUCTURES

      
Document Number 03192441
Status Pending
Filing Date 2021-09-13
Open to Public Date 2022-03-17
Owner
  • THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
  • THE GENERAL HOSPITAL CORPOATION (USA)
Inventor
  • Shafiee, Hadi
  • Bormann, Charles
  • Kanakasabapathy, Manoj Kumar
  • Thirumalaraju, Prudhvi

Abstract

Systems and methods are provided for determining a clinical parameter representing the location of interest within a reproductive cellular structure. An image of the reproductive cellular structure is obtained and provided to a neural network to generate the clinical parameter. The clinical parameter is stored on a non-transitory computer readable medium.

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

31.

RECOMBINANT ADENO ASSOCIATED VIRUS ENCODING CLARIN-1 AND USES THEREOF

      
Document Number 03116391
Status Pending
Filing Date 2021-04-27
Open to Public Date 2022-03-14
Owner
  • PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Corey, David P.
  • Maguire, Casey A.
  • Hanlon, Killian S.
  • Ivanchenko, Maryna V.

Abstract

Aspects of the disclosure relate to compositions and methods for treating hereditary hearing loss and/or vision loss, for example, due to Usher syndrome, Type 3A. In some embodiments, the disclosure provides a recombinant adeno-associated virus comprising: (i) an AAV-S capsid protein, and (ii) an isolated nucleic acid comprising a transgene (e.g., a transgene for expressing a clarin-1 protein). The present disclosure also provides methods of treating hereditary hearing loss and/or vision loss (e.g., Usher Syndrome, Type 3A) using the same.

IPC Classes  ?

  • C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61P 27/00 - Drugs for disorders of the senses
  • C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
  • C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 15/12 - Genes encoding animal proteins
  • C12N 15/35 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
  • C12N 15/864 - Parvoviral vectors

32.

METHODS FOR IDENTIFYING CROSS-MODAL FEATURES FROM SPATIALLY RESOLVED DATA SETS

      
Document Number 03190344
Status Pending
Filing Date 2021-09-02
Open to Public Date 2022-03-10
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Sirbulescu, Ruxandra F.
  • Hess, Josh
  • Reeves, Patrick M.
  • Poznansky, Mark C.

Abstract

Disclosed are methods of identifying a cross-modal feature from two or more spatially resolved data sets, the method including: (a) registering the two or more spatially resolved data sets to produce an aligned feature image including the spatially aligned two or more spatially resolved data sets; and (b) extracting the cross-modal feature from the aligned feature image.

IPC Classes  ?

  • G06T 7/33 - Determination of transform parameters for the alignment of images, i.e. image registration using feature-based methods
  • G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
  • G16B 40/00 - ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
  • G16C 20/70 - Machine learning, data mining or chemometrics
  • G06V 10/762 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using clustering, e.g. of similar faces in social networks
  • G06V 10/77 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using data integration or data reduction, e.g. principal component analysis [PCA] or independent component analysis [ICA] or self-organising maps [SOM]; Blind source separation
  • G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts

33.

TR-FRET BASED ASSAY FOR DETECTION OF ANTIBODIES IN SEROLOGICAL SAMPLES

      
Document Number 03188225
Status Pending
Filing Date 2021-08-16
Open to Public Date 2022-02-24
Owner
  • DANA-FARBER CANCER INSTITUTE, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
Inventor
  • Fischer, Eric
  • Nowak, Radoslaw
  • Yue, Hong
  • Overwijn, Daan
  • Mazitschek, Ralph
  • Payne, Neil Connor

Abstract

The present invention relates to a homogeneous, time resolved, Förster resonance energy transfer (TR-FRET)-based method for detection of SARS-CoV-2, SARS CoV-1, and MERS-CoV antibodies in a patient fluid sample.

IPC Classes  ?

  • G01N 21/64 - Fluorescence; Phosphorescence
  • G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
  • G01N 33/542 - Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
  • G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

34.

SALT INDUCIBLE KINASE INHIBITORS

      
Document Number 03190172
Status Pending
Filing Date 2021-08-05
Open to Public Date 2022-02-10
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Wein, Marc Nathan
  • Greenlee, William J.

Abstract

The present application provides compounds that modulate the activity of one or more salt inducible kinases (SIKs). Pharmaceutical composition and methods of treating diseases associated with abnormal expression and/or activity of one or more SIKs are also provided.

IPC Classes  ?

  • C07D 471/04 - Ortho-condensed systems
  • A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
  • A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
  • A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
  • A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
  • A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
  • A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
  • A61K 31/501 - Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
  • A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
  • A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
  • A61P 35/00 - Antineoplastic agents
  • A61P 37/02 - Immunomodulators
  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
  • C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
  • C07D 471/10 - Spiro-condensed systems
  • C07D 487/04 - Ortho-condensed systems
  • C07D 487/10 - Spiro-condensed systems
  • C07D 498/20 - Spiro-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

35.

INTESTINAL ALKALINE PHOSPHATASES AND METHODS OF USE IN INHIBITING LIVER FIBROSIS

      
Document Number 03190489
Status Pending
Filing Date 2021-07-29
Open to Public Date 2022-02-03
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Hodin, Richard A.

Abstract

The present disclosure relates, inter alia, to therapeutic alkaline phosphatases for the treatment of liver fibrosis.

IPC Classes  ?

36.

ENHANCED VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS

      
Document Number 03189601
Status Pending
Filing Date 2021-07-26
Open to Public Date 2022-01-27
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
Inventor
  • Joung, J., Keith
  • Cabeceiras, Peter

Abstract

Enhanced virus-like particles (eVLPs), comprising a membrane comprising a phospholipid bilayer with one or more virally-derived glycoproteins on the external side; and a cargo disposed in the core of the eVLP on the inside of the membrane, wherein the eVLP does not comprise an exogenous gag/pol protein, and methods of use thereof for delivery of the cargo to cells.

IPC Classes  ?

  • C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
  • A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K 9/51 - Nanocapsules
  • A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K 14/01 - DNA viruses
  • C07K 14/10 - Hepatitis A virus
  • C07K 14/155 - Lentiviridae, e.g. human immunodeficiency virus (HIV), visna-maedi virus, equine infectious anaemia virus
  • C07K 14/16 - HIV-1

37.

TUNNELING NANOTUBE CELLS AND METHODS OF USE THEREOF FOR DELIVERY OF BIOMOLECULES

      
Document Number 03187571
Status Pending
Filing Date 2021-06-23
Open to Public Date 2021-12-30
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Joung, J. Keith
  • Cabeceiras, Peter

Abstract

Tunneling nanotube (TNT) cells, comprising a TNT promoting factor (TPF); and a biomolecule cargo overexpressed by the TNT cell, and methods of use thereof for delivery of the biomolecule cargo from TNT cells to neighboring cells.

IPC Classes  ?

  • C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
  • B01D 69/14 - Dynamic membranes
  • G01N 15/08 - Investigating permeability, pore volume, or surface area of porous materials

38.

TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM

      
Document Number 03181979
Status Pending
Filing Date 2021-06-16
Open to Public Date 2021-12-23
Owner
  • DANA FARBER CANCER INSTITUTE, INC. (USA)
  • THE GENERAL HOSPITAL CORPOATION (USA)
Inventor
  • Ferguson, Fleur M.
  • Gray, Nathanael S.
  • Zhang, Tinghu
  • Haggarty, Stephen J.

Abstract

Disclosed are bispecific compounds (degraders) that target ?-synuclein protein for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat neurodegenerative diseases.

IPC Classes  ?

  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

39.

CHIMERIC AMPLICON ARRAY SEQUENCING

      
Document Number 03182741
Status Pending
Filing Date 2021-06-14
Open to Public Date 2021-12-23
Owner
  • THE BROAD INSTITUTE, INC. (USA)
  • MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
  • THE GENERAL HOSPITAL CORPORATION - DBA MASS GENERAL HOSPITAL (USA)
Inventor
  • Al'Khafaji, Aziz
  • Blainey, Paul
  • Babadi, Mehrtash
  • Garimella, Kiran V
  • Hacohen, Nir
  • Smith, Jonathan Theodore

Abstract

The present disclosure relates to compositions and methods for nucleic acid sequencing, and specifically, at least in certain aspects, provides methods and compositions for enhancing the efficacy, throughput and/or yield of known long-range sequencing platforms, by providing chimeric arrays of input sequences. Such arrays of component nucleic acid sequence elements can be prepared via methods that minimize introduction of bias. The application of the current methods to obtain isoform sequencing information, e.g., from patient samples is specifically also provided, as are methods for mitochondrial lineage tracing that employ the instant chimeric amplicon sequencing processes. Methods and systems for array nucleic acid sequence processing and interpretation are also provided.

IPC Classes  ?

  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

40.

ORAL APPLIANCE AND METHOD FOR TREATING SLEEP DISORDERS

      
Document Number 03183014
Status Pending
Filing Date 2021-06-17
Open to Public Date 2021-12-23
Owner
  • UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
  • MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
  • THE GENERAL HOSPITAL CORPORATION D.B.A MASSACHUSETTS GENERAL HOSPITAL (USA)
Inventor
  • Rasalingam, Ravi
  • Ward, Tarsha
  • Roche, Ellen T.
  • Venegas, Jose

Abstract

An oral appliance and method for treating a sleep disorder in a subject are disclosed. The appliance includes, among other elements, a palatal overlay element that engages a portion of the dorsal surface of the subject's tongue, stabilizing the tongue in a superior direction toward the hard palate. The method generally involves stabilizing the dorsal surface of a subject's tongue in a superior direction toward the subject's hard palate.

IPC Classes  ?

  • A61C 5/90 - Oral protectors for use during treatment, e.g. lip or mouth protectors
  • A61F 5/56 - Devices for preventing snoring
  • A61M 16/06 - Respiratory or anaesthetic masks
  • A62B 9/06 - Mouthpieces; Nose-clips

41.

ARRDC1-MEDIATED MICROVESICLE-BASED DELIVERY TO THE NERVOUS SYSTEM

      
Document Number 03181861
Status Pending
Filing Date 2021-06-11
Open to Public Date 2021-12-16
Owner
  • PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
  • GENERAL HOSPITAL CORPORATION (USA)
  • VESIGEN, INC. (USA)
Inventor
  • Lu, Quan
  • Haggarty, Stephen J.
  • Millman, Robert

Abstract

Methods, systems, compositions and strategies for the use of ARMM-mediated delivery of molecules (e.g., biological molecules, small molecules, proteins, and nucleic acids (e.g., DNA, RNA), DNA plasmids shRNA, mRNA) to cells of the nervous system (e.g., central nervous system and peripheral nervous system).

IPC Classes  ?

  • A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

42.

GLUTATHIONE TRISULFIDE (GSSSG) IN NEUROPROTECTION

      
Document Number 03182905
Status Pending
Filing Date 2021-05-11
Open to Public Date 2021-11-18
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Ichinose, Fumito
  • Marutani, Eizo

Abstract

Methods for the use of glutathione trisulfide (GSSSG) in neuroprotection, e.g., in neurodegenerative diseases and to reduce the risk of ischemic injury. The methods can be used, e.g., to reduce risk of injury to brain, spinal cord, and peripheral nerves from ischemia or low blood flow states possibly caused by surgery, trauma, and other conditions that decrease/impair blood flow and or oxygen delivery to the nervous system.

IPC Classes  ?

  • C07K 5/093 - Tripeptides the side chain of the first amino acid containing more carboxyl groups than amino groups, or derivatives thereof, e.g. Asp, Glu, Asn
  • A61K 38/06 - Tripeptides
  • C07K 5/08 - Tripeptides

43.

FREQUENCY-COMB GENERATION BASED ON ELECTRO-OPTIC PHASE-CODE MODE-LOCKING FOR CIRCULAR-RANGING OCT

      
Document Number 03162012
Status Pending
Filing Date 2021-01-29
Open to Public Date 2021-09-30
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Vakoc, Benjamin
  • Kim, Tae Shik

Abstract

A source for providing electromagnetic radiation within a particular spectral range, including: a ring-shaped optical resonator for circulating a plurality of wavelength bands including: a first optical phase modulator, a first chromatic dispersion device, a second optical phase modulator, a multi-line spectral domain filter, a second chromatic dispersion device, and an optical amplifier; a controller coupled to the first optical phase modulator and the second optical phase modulator which is configured to drive the first optical phase modulator with a first waveform and the second optical phase modulator with a second waveform, the first chromatic dispersion device being configured between the first optical phase modulator and the second optical phase modulator to provide chromatic dispersion so as to subject each of the plurality of wavelength bands to a respective plurality of different time delays, the first optical phase modulator and the second optical phase modulator being configured to create spectral broadening by the first optical phase modulator of each of the plurality of wavelength bands and spectral recovery by the second optical phase modulator of a particular wavelength band of the plurality of wavelength bands by modulating a first phase using the first optical phase modulator driven by the first waveform and, after a particular time delay, modulating a second phase using the second optical phase modulator driven by the second waveform comprising an inverse of the first waveform, the particular time delay being determined so as to create spectral recovery for the particular wavelength band of the plurality of wavelength bands, the multi-line spectral domain filter being configured to provide multi-line spectral filtering with narrow bandwidths in order to induce power loss for each of the plurality of wavelength bands except for the particular wavelength band, the second chromatic dispersion device being configured to provide chromatic dispersion compensation to an output of the multi-line spectral domain filter in order to compensate a group delay dispersion within the optical resonator and match a roundtrip frequency for each of the plurality of wavelength bands, and the first and second waveforms being configured to create a periodic phase modulation for recovery of the plurality of wavelength bands at a frequency that is an integer multiple of a roundtrip frequency of the optical resonator.

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • G01B 9/02 - Interferometers
  • G01K 11/32 - Measuring temperature based on physical or chemical changes not covered by group , , , or using changes in transmittance, scattering or luminescence in optical fibres
  • G02B 6/293 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals with wavelength selective means
  • H01S 3/106 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating by controlling devices placed within the cavity

44.

TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3

      
Document Number 03171337
Status Pending
Filing Date 2021-03-17
Open to Public Date 2021-09-23
Owner
  • DANA-FARBER CANCER INSTITUTE, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Ferguson, Fleur M.
  • Gray, Nathanael S.
  • Haggarty, Stephen J.
  • Telo Baptista Lima Da Silva, Maria Catarina

Abstract

Disclosed are bispecific compounds (degraders) that target tau protein for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat neurodegenerative and neuropsychiatric diseases associated with aberrant tau.

IPC Classes  ?

  • A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin

45.

SYSTEMS AND METHODS FOR A HAIR TRANSPLANT SYSTEM WITH EXTRACTION AND IMPLANTATION NEEDLES

      
Document Number 03172547
Status Pending
Filing Date 2021-02-22
Open to Public Date 2021-08-26
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Franco, Walfre
  • Ibarra-Silva, Esmeralda
  • Farinelli, William A.
  • Tam, Joshua
  • Anderson, Richard Rox
  • Drake, Lynn
  • Korupolu, Sandeep

Abstract

Systems and methods are provided for performing a hair transplant using a hair transplant device. The hair transplant device comprises an extraction unit including a coring needle configured to extract at least one hair follicle from a donor site, an implanting unit removably coupled to the extraction unit, the implanting unit including a splitting needle configured to create an opening in a recipient site, a housing coupled to the extraction unit, and a user interface extending from the housing and moveable relative to the housing. The user interface includes a pin movable within the coring needle relative to the housing.

IPC Classes  ?

46.

HIGHLY EFFICIENT MYELOPEROXIDASE ACTIVATABLE IMAGING AGENTS

      
Document Number 03162412
Status Pending
Filing Date 2020-12-16
Open to Public Date 2021-06-24
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Chen, John W.
  • Wang, Cuihua

Abstract

Provided herein are compounds useful as imaging agents. Exemplary compounds provided herein are useful as myeloperoxidase imaging agents using magnetic resonance or nuclear imaging techniques. Methods for preparing the compounds provided herein and diagnostic methods using the compounds are also provided.

IPC Classes  ?

  • A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes

47.

SYSTEMS, METHODS, AND MEDIA FOR MULTIPLE BEAM OPTICAL COHERENCE TOMOGRAPHY

      
Document Number 03158522
Status Pending
Filing Date 2020-12-21
Open to Public Date 2021-06-24
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Vakoc, Benjamin
  • Kim, Yongjoo

Abstract

Systems, methods, and media for multiple beam optical coherence tomography are provided which, in some embodiments, include: a light source; a splitter that outputs a fraction of light to various waveguides; optical components that receive light from the waveguides and direct the light as beams that simultaneously impinge a sample at different lateral positions, and collect backscattered light from the lateral positons; another splitter that outputs a fraction of light to waveguides of a reference arm as reference light samples; a mixer that receives the backscattered light samples and the reference light samples, and combines each backscattered sample with a corresponding reference sample such that the mixer outputs fringes; and a detector that receives the fringes, and outputs OCT signals, each indicative of a structure of the sample at a respective lateral position.

IPC Classes  ?

48.

COMPOSITIONS AND METHODS FOR TUNABLE MAGNETIC NANOPARTICLES

      
Document Number 03163946
Status Pending
Filing Date 2020-12-07
Open to Public Date 2021-06-10
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Mattingly, Eli
  • Yoo, Byunghee
  • Medarova, Zdravka
  • Yigit, Mehmet V.

Abstract

The present disclosure presents nanoparticle compositions for use in the treatment, prevention, or imaging of a disease (e.g., cancer), methods of treating, preventing, or imaging a disease in a subject in need thereof with the nanoparticle compositions, and methods of preparing the nanoparticle compositions of the disclosure. The nanoparticle compositions can include a magnetic nanoparticle ferric chloride, ferrous chloride, or a combination thereof, and a dextran coating functionalized with one or more amine groups.

IPC Classes  ?

  • A61K 49/12 - Macromolecular compounds
  • A61K 33/26 - Iron; Compounds thereof
  • A61K 47/36 - Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • G01N 33/548 - Carbohydrates, e.g. dextran

49.

SYSTEM AND METHOD FOR ACTIVATING GENE EXPRESSION

      
Document Number 03163087
Status Pending
Filing Date 2020-11-25
Open to Public Date 2021-06-03
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Joung, J. Keith
  • Tak, Y. Esther

Abstract

Provided herein are artificial transcription factor systems and related methods for modulating gene expression.

IPC Classes  ?

  • C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • A61K 38/46 - Hydrolases (3)
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • C07K 19/00 - Hybrid peptides
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 9/22 - Ribonucleases
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

50.

COMPOSITIONS AND METHODS FOR REGULATING EGFR AMPLIFICATION IN CANCER CELLS FOR IMPROVING EGFR-TARGETED ANTI-CANCER AGENT

      
Document Number 03158438
Status Pending
Filing Date 2020-11-16
Open to Public Date 2021-05-20
Owner
  • INSTITUTE FOR CANCER RESEARCH (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Whetstine, Johnathan R.
  • Clarke, Thomas L.

Abstract

Compositions and methods for regulating EGFR amplification in cancer are disclosed.

IPC Classes  ?

  • C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
  • C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
  • A61P 35/04 - Antineoplastic agents specific for metastasis

51.

RESOLVING ABSOLUTE DEPTH IN CIRCULAR-RANGING OPTICAL COHERENCE TOMOGRAPHY

      
Document Number 03155685
Status Pending
Filing Date 2020-10-30
Open to Public Date 2021-05-06
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Vakoc, Benjamin
  • Lippok, Norman

Abstract

An apparatus, including: an electromagnetic radiation source producing radiation for illuminating a sample located at an optical path depth, the electromagnetic radiation source providing the radiation to the sample to facilitate determining the optical path depth within the sample: an interferometer including: a reference arm a first portion of the radiation is delivered to, a sample arm to which a second portion of the radiation is delivered, a first optical subsystem coupled to the sample arm to interrogate the sample with the radiation delivered to the sample arm and to collect backscattered radiation from the sample, and a second optical subsystem coupled to the reference arm and the first optical subsystem to generate interference fringes between the collected backscattered radiation and the radiation delivered to the reference arm; and a data collection and processing system configured to compute the optical path depth of the sample from the received interference fringes.

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • G01B 9/02 - Interferometers
  • G01B 11/22 - Measuring arrangements characterised by the use of optical techniques for measuring depth
  • G01J 3/45 - Interferometric spectrometry

52.

HIGH-THROUGHPUT CULTURE OF IPSC-DERIVED ALVEOLAR CELLS

      
Document Number 03159195
Status Pending
Filing Date 2020-10-30
Open to Public Date 2021-05-06
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Ott, Harald C.
  • Jeffs, Sydney

Abstract

Provided herein are floating hydrogel droplet culture methods that enable scaling of stem cell derived alveolar epithelial cell (AEC) expansion to numbers compatible with large animal or human whole lung engineering, as well as molds for generating the droplets and methods of use thereof.

IPC Classes  ?

  • C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
  • C12N 5/074 - Adult stem cells
  • C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means

53.

CAL-T CONSTRUCTS AND USES THEREOF

      
Document Number 03151961
Status Pending
Filing Date 2020-10-16
Open to Public Date 2021-04-22
Owner
  • TRUSTEES OF BOSTON UNIVERSITY (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Pakyari, Mohammadreza
  • Cetrulo, Curtis
  • Wong, Wilson
  • Okuma, Atsushi

Abstract

The technology described herein is directed to compositions comprising components of multi-compoent CALs or CARs, e.g., a TCR recognition domain; and one or both of: (a) an intracellular signaling domain; and (b) a first-type protein interaction domain. Further provided herein are methods for treating or preventing an autoimmune disease, a transplant rejection, or graft versus host disease.

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

54.

WS-635 USES THEREOF IN MEDICINE

      
Document Number 03128410
Status Pending
Filing Date 2019-10-11
Open to Public Date 2021-04-15
Owner
  • WATERSTONE PHARMACEUTICALS (WUHAN) CO., LTD. (China)
  • THE GENERAL HOSPITAL CORPORATIN (USA)
Inventor
  • Zhang, Faming
  • Cui, Jian
  • Yu, Yao
  • Hu, Minglong
  • Xie, Zhongcong

Abstract

The present invention provides a method of treating, preventing, or lessening postoperative cognitive dysfunction (POCD) in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically effective amount of a compound of Formula I or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof,

IPC Classes  ?

  • A61K 38/13 - Cyclosporins
  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

55.

COMPOSITIONS AND METHODS FOR PULMONARY SURFACTANT-BIOMIMETIC NANOPARTICLES

      
Document Number 03157192
Status Pending
Filing Date 2020-10-06
Open to Public Date 2021-04-15
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Wu, Mei Xiong

Abstract

Compositions and methods comprising Pulmonary Surfactant (PS)-biomimetic nanoparticles are disclosed. Specifically, the disclosure is related to a composition comprising a nanoparticle with an average size of 200-400 nm, including a plurality of pulmonary surfactant biomimetic molecules, wherein the nanoparticle is negatively charged; and one or more cargo molecules that are enveloped by the nanoparticle, wherein the cargo molecule has a molecular weight up to 1200 Da.

IPC Classes  ?

  • A61K 9/127 - Liposomes
  • A61K 9/16 - Agglomerates; Granulates; Microbeadlets
  • A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K 9/50 - Microcapsules
  • A61K 33/24 - Heavy metals; Compounds thereof
  • A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
  • A61P 35/00 - Antineoplastic agents

56.

AUTOMATED EVALUATION OF QUALITY ASSURANCE METRICS FOR ASSISTED REPRODUCTION PROCEDURES

      
Document Number 03150083
Status Pending
Filing Date 2020-09-08
Open to Public Date 2021-03-11
Owner
  • THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Shafiee, Hadi
  • Bormann, Charles L.
  • Kanakasabapathy, Manoj Kumar
  • Thirumalaraju, Prudhvi

Abstract

Systems and methods are provided for assigning a quality parameter to a reproductive cellular structure. An image of the reproductive cellular structure is obtained. The image of the reproductive cellular structure is provided to a neural network to generate a value representing a morphology of the reproductive cellular structure. The value is compared to a predefined standard to provide a quality assurance metric representing one of a medical personnel, a facility, a growth medium, and an identity of the reproductive cellular structure.

IPC Classes  ?

57.

TARGETING THE GASTROINTESTINAL BARRIER TO TREAT AGE-RELATED DISORDERS

      
Document Number 03148988
Status Pending
Filing Date 2020-07-30
Open to Public Date 2021-02-11
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Hodin, Richard A.

Abstract

The disclosure provides various aspects and embodiments of methods of, and compositions for use in methods of, treating age-related physiological alterations (e.g., those associated with age-related diseases or disorders) and/or treating or delaying the onset of age-related frailty in a subject. The methods include administering an AP-based agent or composition (e.g., a bovine intestinal alkaline phosphatase).

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
  • C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)

58.

SELF-ASSEMBLED VACCINES AND COMBINATION THERAPIES FOR TREATING CANCER

      
Document Number 03147874
Status Pending
Filing Date 2020-07-17
Open to Public Date 2021-01-28
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Poznansky, Mark C.
  • Gelfand, Jeffrey A.
  • Leblanc, Pierre R.
  • Korochkina, Svetlana E.

Abstract

Provided herein are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non- covalently bound to a biotinylated component (e.g, tumor cell, tumor antigen, virus or viral antigen). The self-assembling pharmaceutical compositions may further comprise an immunotherapy (e.g, anti-PD-1 antibody). In addition, methods of using these pharmaceutical compositions to prevent and/or treat cancer, or to induce an immune response are provided. Methods of using the self-assembling pharmaceutical compositions in combination with an immunotherapy (e.g., anti-PD-1 antibody) are also provided.

IPC Classes  ?

  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61P 35/00 - Antineoplastic agents

59.

ENGINEERED HUMAN-ENDOGENOUS VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS

      
Document Number 03143327
Status Pending
Filing Date 2020-06-15
Open to Public Date 2020-12-17
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
Inventor
  • Joung, J. Keith
  • Cabeceiras, Peter

Abstract

Human-derived virus-like particles (heVLPs), comprising a membrane comprising a phospholipid bilayer with one or more HERV-derived envelope proteins on the external side; one or more HERV-derived GAG proteins in the heVLP core, and a cargo molecule, e.g., a biomolecule and/or chemical cargo molecule, disposed in the core of the heVLP on the inside of the membrane, wherein the heVLP does not comprise a gag protein, except for gag proteins that are encoded in the human genome or gag proteins that are encoded by a consensus sequence that is derived from gag proteins found in the human genome, and methods of use thereof for delivery of the cargo molecule to cells.

IPC Classes  ?

  • A61K 35/76 - Viruses; Subviral particles; Bacteriophages
  • A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K 38/43 - Enzymes; Proenzymes; Derivatives thereof
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 15/52 - Genes encoding for enzymes or proenzymes
  • C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts

60.

ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS THAT TARGET TACI

      
Document Number 03139057
Status Pending
Filing Date 2020-06-04
Open to Public Date 2020-12-10
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Maus, Marcela V.
  • Larson, Rebecca

Abstract

The invention provides antibodies, antibody-drug conjugates, bispecific T cell engagers (BiTEs), and chimeric antigen receptors (CARs) that target transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). Such antibodies, antibody-drug conjugates, BiTEs, and CARs can be used, e.g., in methods for treating a cancer (e.g., multiple myeloma), an autoimmune disorder (e.g., characterized by a high titer of antibodies contributing to the disorder), or a plasma cell disease disorder (e.g., plasma cell dyscrasias) in a subject in need thereof.

IPC Classes  ?

  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K 16/46 - Hybrid immunoglobulins
  • C07K 19/00 - Hybrid peptides

61.

GENE THERAPY FOR ALZHEIMER'S DISEASE

      
Document Number 03141712
Status Pending
Filing Date 2020-05-21
Open to Public Date 2020-12-03
Owner
  • THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Shen, Jie
  • Kelleher Iii, Raymond J.

Abstract

The present disclosure provides, among other things, human codon-optimized sequences encoding presenilin 1, and methods for using the sequences in gene therapy to treat neurodegenerative diseases including, but not limited to Alzheimer's disease, frontotemporal dementia, frontotemporal lobar degeneration, Pick's disease, Lewy body dementia, memory loss, and cognitive impairment including mild cognitive impairment (MCI).

IPC Classes  ?

  • C12N 15/12 - Genes encoding animal proteins
  • A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
  • C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
  • C12N 15/57 - Hydrolases (3) acting on peptide bonds (3.4)
  • C12N 15/67 - General methods for enhancing the expression
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N 15/86 - Viral vectors
  • C12N 15/864 - Parvoviral vectors

62.

APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF

      
Document Number 03141988
Status Pending
Filing Date 2020-05-28
Open to Public Date 2020-12-03
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • BANNER HEALTH (USA)
  • THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (USA)
Inventor
  • Quiroz, Yakeel T.
  • Arboleda-Velasquez, Joseph F.
  • Reiman, Eric M.
  • Lopera, Francisco

Abstract

Methods and compositions for preventing or treating cognitive decline associated with dementia and/or mild cognitive impairment and/or neurodegeneration using antibodies, peptides, fusion proteins, or genome editing systems that modulate HSPG/heparin binding affinities of ApoE.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07K 14/775 - Apolipopeptides
  • C07K 19/00 - Hybrid peptides
  • C12N 15/13 - Immunoglobulins
  • C12N 15/62 - DNA sequences coding for fusion proteins
  • C12P 21/08 - Monoclonal antibodies

63.

TEAC AND ATTAC IMMUNOONCOLOGY COMPOSITIONS AND METHODS

      
Document Number 03138854
Status Pending
Filing Date 2020-04-23
Open to Public Date 2020-11-05
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • REVITOPE LIMITED (United Kingdom)
Inventor
  • Cobbold, Mark
  • Preyer, Martin
  • Colthart, Allison

Abstract

The present disclosure provides targeted T-cell engaging agents (TEAC) and antibody tumor-targeting assembly complexes (ATTAC) for targeting to cancer. The TEAC or ATTAC described herein may have, for example, longer half-life or comprise multiple components in a single agent.

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

64.

GHRH OR ANALOGUES THEREOF FOR USE IN TREATMENT OF HEPATIC DISEASE

      
Document Number 03133319
Status Pending
Filing Date 2020-03-27
Open to Public Date 2020-10-08
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Grinspoon, Steven K.

Abstract

The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., frans-3-hexenoyl-GHRH(1-44)-NH2, or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.

IPC Classes  ?

  • A61K 38/25 - Growth hormone-releasing factor [GH-RF] (Somatoliberin)
  • A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • C07K 14/60 - Growth hormone-releasing factor (GH-RF) (Somatoliberin)

65.

METHODS TO ENHANCE T CELL REGENERATION

      
Document Number 03135618
Status Pending
Filing Date 2020-04-01
Open to Public Date 2020-10-08
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
Inventor
  • Scadden, David T.
  • Gustafsson, Karin

Abstract

Described herein are methods for the restoration of T cell production in a subject in need thereof.

IPC Classes  ?

  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
  • A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

66.

ENGINEERED ADENO-ASSOCIATED (AAV) VECTORS FOR TRANSGENE EXPRESSION

      
Document Number 03135292
Status Pending
Filing Date 2020-03-30
Open to Public Date 2020-10-01
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
Inventor
  • Maguire, Casey A.
  • Hudry, Eloise Marie
  • Hanlon, Killian S.

Abstract

Engineered AAV vectors for transgene expression, e.g., in the CNS, PNS, inner ear, heart, or retina, and methods of use thereof. Also provided are methods for discovering new engineered AAV vectors that mediate transgene expression in desired cell types.

IPC Classes  ?

  • C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
  • C12N 15/86 - Viral vectors

67.

INTRAOPERATIVE CLINICAL DECISION SUPPORT SYSTEM

      
Document Number 03135183
Status Pending
Filing Date 2020-03-27
Open to Public Date 2020-10-01
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
Inventor
  • Nanji, Karen C.
  • Bates, David W.

Abstract

Systems and methods are provided for intraoperative real-time clinical decision support. A system includes a processor, a non-transitory computer readable medium, storing executable instructions, and an output device. An interface is configured to receive a first set of patient data in real-time from at least one sensor monitoring vital signals of a patient during a surgical procedure and a second set of patient data in real-time from an anesthesia machine during the surgical procedure. An input interface receives an indicator representing at least an identity of a therapeutic to be administered to the patient. A machine learning model determines from the indicator, the first set of patient data, and the second set of patient data if an alert should be provided to a user. The output device provides the alert to the user if the machine learning model determines that the alert should be provided.

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • A61B 5/024 - Measuring pulse rate or heart rate
  • A61M 21/02 - Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia
  • A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body

68.

NOVEL SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS

      
Document Number 03133753
Status Pending
Filing Date 2020-03-13
Open to Public Date 2020-09-24
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Maiti, Pranab
  • Abbineni, Chandrasekhar
  • Talluri, Krishna Chaitanya
  • Panigrahi, Sunil Kumar
  • Wu, Xu
  • Jarugumilli, Gopala Krishna
  • Sun, Yang

Abstract

The present disclosure compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the TEAD transcription factor, and are useful in the treatment of diseases related to the activity of TEAD transcription factor including, e.g., cancer and other diseases.

IPC Classes  ?

  • C07D 213/79 - Acids; Esters
  • A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
  • A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
  • A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
  • A61K 31/245 - Amino benzoic acid types, e.g. procaine, novocaine
  • A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
  • A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K 31/404 - Indoles, e.g. pindolol
  • A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
  • A61K 31/415 - 1,2-Diazoles
  • A61K 31/426 - 1,3-Thiazoles
  • A61K 31/44 - Non-condensed pyridines; Hydrogenated derivatives thereof
  • A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
  • A61K 31/4965 - Non-condensed pyrazines
  • A61K 31/505 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
  • A61K 31/63 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide
  • A61P 35/00 - Antineoplastic agents
  • C07C 229/58 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho- position having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of a six-membered aromatic ring, e.g. N-phenyl-anthranilic acids
  • C07C 229/60 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
  • C07C 237/40 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
  • C07C 311/44 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
  • C07C 317/36 - Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
  • C07C 381/12 - Sulfonium compounds
  • C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
  • C07D 207/04 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D 209/04 - Indoles; Hydrogenated indoles
  • C07D 211/06 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
  • C07D 213/82 - Amides; Imides in position 3
  • C07D 213/84 - Nitriles
  • C07D 231/38 - Nitrogen atoms
  • C07D 235/06 - Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
  • C07D 239/47 - One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
  • C07D 239/48 - Two nitrogen atoms
  • C07D 241/20 - Nitrogen atoms
  • C07D 277/42 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
  • C07D 295/155 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
  • C07D 309/14 - Nitrogen atoms not forming part of a nitro radical
  • C07D 471/04 - Ortho-condensed systems
  • C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

69.

TREATMENT OF BENIGN NERVOUS SYSTEM TUMORS USING ATTENUATED SALMONELLA TYPHIMURIUM

      
Document Number 03131699
Status Pending
Filing Date 2020-02-27
Open to Public Date 2020-09-03
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Brenner, Gary J.
  • Ahmed, Sherif

Abstract

Compositions and methods for the treatment of benign nervous system tumors including schwannomas using attenuated Salmonella typhimurium and optionally one or more checkpoint inhibitors.

IPC Classes  ?

  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61K 39/112 - Salmonella; Shigella
  • C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

70.

CAROTENOIDS FOR TREATING OR PREVENTING NAUSEA

      
Document Number 03128277
Status Pending
Filing Date 2019-05-10
Open to Public Date 2020-08-13
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Ruvkun, Gary B.
  • Govindan, Jothi Amaranath
  • Jayamani, Elamparithi

Abstract

The present disclosure provides technologies relating to treatment of nausea and/or vomiting, and in some embodiments relates in particular to induced (e.g., chemotherapy-induced) nausea and/or vomiting. Alternatively, or additionally, in some embodiments, provides technologies relating to treatment or prevention of one or more feeding disorders (e.g., anorexia nervosa). Also provided herein are therapeutic compositions for oral delivery comprising a therapeutically effective amount of a C50 carotenoid compound, and a pharmaceutically acceptable carrier.

IPC Classes  ?

  • A61K 31/047 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
  • A61K 35/74 - Bacteria
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
  • A61P 1/08 - Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
  • A61P 25/00 - Drugs for disorders of the nervous system
  • C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • G01N 33/48 - Biological material, e.g. blood, urine; Haemocytometers

71.

TRANSPOSON-BASED MODIFICATIONS OF IMMUNE CELLS

      
Document Number 03129263
Status Pending
Filing Date 2020-02-07
Open to Public Date 2020-08-13
Owner
  • DNA TWOPOINTO INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Cobbold, Mark
  • Lee, Maggie
  • Minshull, Jeremy
  • Shi, Feng
  • Shui, Yifang

Abstract

The present invention provides methods and compositions for stable genetic modification of immune cells. The genetic modifications can be used to produce immune cells for therapeutic or diagnostic purposes.

IPC Classes  ?

  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • A61K 35/14 - Blood; Artificial blood
  • C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 15/12 - Genes encoding animal proteins
  • C12N 15/867 - Retroviral vectors

72.

COMPOSITIONS, METHODS AND KITS FOR STABILIZING CELLS AND BIOLOGICAL SAMPLES

      
Document Number 03129428
Status Pending
Filing Date 2020-02-07
Open to Public Date 2020-08-13
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • SAPERE BIO, INC. (USA)
Inventor
  • Toner, Mehmet
  • Sandlin, Rebecca
  • Knecht, Anne
  • Wong, Ho Ki Keith
  • Tessier, Shannon N.
  • Stott, Shannon

Abstract

Compositions, methods and kits are described for stabilizing cells and biological samples, allowing for storage and transportation of stabilized cells and biological samples. Cells can be stabilized in whole blood or fractionated blood. Isolated cells can also be stabilized.

IPC Classes  ?

  • A01N 1/00 - Preservation of bodies of humans or animals, or parts thereof
  • A01N 1/02 - Preservation of living parts

73.

B CELL IMMUNOTHERAPY

      
Document Number 03127623
Status Pending
Filing Date 2020-01-23
Open to Public Date 2020-07-30
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • HOLY CROSS HOSPITAL, INC. (USA)
Inventor
  • Poznansky, Mark C.
  • Sirbulescu, Ruxandra F.

Abstract

The invention, in general, features a method of treating a neurodegenerative disease (such as amyotrophic lateral sclerosis) or a traumatic brain injury in a subject (e.g., a human) in need thereof, the method comprising administering to the subject a therapeutically effective amount of isolated B cells (such as autologous or allogeneic or xenogeneic B cells).

IPC Classes  ?

  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • C12N 5/0781 - B cells; Progenitors thereof
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

74.

ANTI-EPHRIN-B2 BLOCKING ANTIBODIES FOR THE TREATMENT OF FIBROTIC DISEASES

      
Document Number 03125160
Status Pending
Filing Date 2019-12-27
Open to Public Date 2020-07-02
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Lagares, David

Abstract

Methods and compositions for treating organ fibrosis using antibodies or antigen-binding fragments thereof that bind to and block the soluble Ephrin B2 ectodomain.

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

75.

PEPTIDE TAGS FOR LIGAND INDUCED DEGRADATION OF FUSION PROTEINS

      
Document Number 03123054
Status Pending
Filing Date 2019-12-18
Open to Public Date 2020-06-25
Owner
  • DANA-FARBER CANCER INSTITUTE, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Jan, Max
  • Ebert, Benjamin L.
  • Fischer, Eric
  • Nowak, Radoslaw

Abstract

Described herein are compositions and methods for modulating protein abundance in a target-specific manner via degron tags.

IPC Classes  ?

  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans

76.

CROMOLYN ESTERS AND USES THEREOF

      
Document Number 03122989
Status Pending
Filing Date 2019-12-10
Open to Public Date 2020-06-18
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Shoup, Timothy M.
  • Elmaleh, David R.

Abstract

Described herein are compounds and methods of treating or imaging a disease or disorder, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of a cromolyn ester.

IPC Classes  ?

  • C07D 311/24 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
  • A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
  • A61K 51/04 - Organic compounds

77.

COMPOSITIONS AND METHODS FOR IMMUNE TOLERANCE

      
Document Number 03120576
Status Pending
Filing Date 2019-11-26
Open to Public Date 2020-06-04
Owner
  • MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Bhatia, Sangeeta N.
  • Chhabra, Arnav
  • Maus, Marcela V.

Abstract

Immunotolerant engineered human tissue constructs are provided that are suitable for implantation into subjects. In some embodiments, the immunotolerance is controllable by an inducible system. Methods of making and using the immunotolerant engineered tissue constructs are provided.

IPC Classes  ?

  • A61F 2/00 - Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61K 35/33 - Fibroblasts
  • A61K 35/407 - Liver; Hepatocytes
  • A61K 35/44 - Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61L 27/00 - Materials for prostheses or for coating prostheses
  • A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
  • C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

78.

CRISPR SYSTEM BASED DROPLET DIAGNOSTIC SYSTEMS AND METHODS

      
Document Number 03119972
Status Pending
Filing Date 2019-11-14
Open to Public Date 2020-05-22
Owner
  • THE BROAD INSTITUTE, INC. (USA)
  • PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
  • MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Myhrvold, Cameron
  • Freije, Catherine Amanda
  • Metsky, Hayden
  • Sabeti, Pardis
  • Thakku, Gowtham
  • Kehe, Jared
  • Ackerman, Cheri
  • Blainey, Paul
  • Hung, Deborah

Abstract

RNA targeting proteins are utilized to provide a robust massively multiplexed CRISPR-based diagnostic by detection in droplets with attomolar sensitivity. Detection of both DNA and RNA with comparable levels of sensitivity at nanoliter volumes can differentiate targets from non-targets based on single base pair differences, with applications in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, and sensitive genotyping.

IPC Classes  ?

  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • C12Q 1/6816 - Hybridisation assays characterised by the detection means
  • C12Q 1/6825 - Nucleic acid detection involving sensors

79.

COMPOSITIONS AND METHODS FOR TREATMENT OF LIVER DISEASE

      
Document Number 03117098
Status Pending
Filing Date 2019-10-18
Open to Public Date 2020-04-23
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Choi, Michael Yoonsuk

Abstract

Described herein are methods and compositions for treating a liver disease. Aspects of the invention relate to administering to a subject an agent that inhibits WISP1. Another aspect of the invention relates to administering to a subject a HSC that expresses and agent that inhibits WISP1.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
  • A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
  • A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
  • A61K 35/407 - Liver; Hepatocytes
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • G01N 33/48 - Biological material, e.g. blood, urine; Haemocytometers

80.

COMPOSITIONS AND METHODS FOR IMMUNE CHECKPOINT INHIBITION

      
Document Number 03111562
Status Pending
Filing Date 2019-09-06
Open to Public Date 2020-04-02
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Medarova, Zdravka
  • Yoo, Byunghee

Abstract

Therapeutic compositions and methods for treating cancer, e.g., pancreatic cancer, that use nanoparticles linked to inhibitory nucleic acids, e.g., siRNAs, targeting an immune checkpoint molecule, e.g., programmed cell death 1 ligand 1 (PD-L1).

IPC Classes  ?

  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61K 9/50 - Microcapsules
  • A61K 49/18 - Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes

81.

METHODS OF TREATING CYTOKINE RELEASE SYNDROME

      
Document Number 03111217
Status Pending
Filing Date 2019-09-05
Open to Public Date 2020-03-12
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • AZTHERAPIES, INC. (USA)
Inventor
  • Elmaleh, David R.
  • Tanzi, Rudolph E.
  • Griciuc, Ana
  • Warren, Robert
  • Reeves, Karen

Abstract

The present disclosure relates to a method of treating at least one condition selected from Cytokine Release Syndrome (CRS), Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS), cancer-related cognitive impairment, Infusion Reaction Syndrome (IRS), Capillary Leak Syndrome (CLS), Tumor Lysis Syndrome (TLS), Macrophage Activation Syndrome (MAS), Systemic Inflammatory Response Syndrome (SIRS), Immune Reconstitution Inflammatory Syndrome (IRIS), Graft-Versus-Host Disease (GVHD), Acute Respiratory Distress Syndrome (ARDS), sepsis, Ebola, avian influenza, smallpox, Systemic Inflammatory Response Syndrome (SIRS), and Immune-related Adverse Events Syndrome (IrAES) in a subject in need thereof, comprising administering a mast cell stabilizer or a compound of Formula I or Formula II: Formula I, Formula II, wherein R1 is halogen, OH, or -OC(O)C1-5alkyl R2 and R3 are each independently selected from CO2R4 or CH2OR5; R4 is Li, Na, K, H, C1-5alkyl, or -CH2CO(C1-5alkyl); and R5 is H or C(O)(C1-5alkyl), or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

  • A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
  • C07D 311/24 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

82.

COMPOSITIONS AND METHODS FOR DETECTING ANTIBIOTIC RESPONSIVE MRNA EXPRESSION SIGNATURES AND USES THEREOF

      
Document Number 03110721
Status Pending
Filing Date 2019-08-26
Open to Public Date 2020-03-05
Owner
  • THE BROAD INSTITUTE, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Hung, Deborah
  • Bhattacharyya, Roby
  • Livny, Jonathan
  • Ma, Peijun

Abstract

The present disclosure relates to compositions, methods, and kits for rapid phenotypic detection of antibiotic resistance/susceptibility.

IPC Classes  ?

  • C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
  • C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
  • C12Q 1/6813 - Hybridisation assays
  • C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C40B 40/06 - Libraries containing nucleotides or polynucleotides, or derivatives thereof
  • G01N 33/15 - Medicinal preparations

83.

ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY POLYPEPTIDES

      
Document Number 03109954
Status Pending
Filing Date 2019-08-20
Open to Public Date 2020-02-27
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Faustman, Denise L.

Abstract

Described are antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T- regs) and/or myeloid-derived suppressor cells (MDSCs), to expand T effector cell populations or function, and to reduce the proliferation of, or directly kill, tumor cells, such as tumor cells that express TNFR2 antigen. The polypeptides, such as antibodies and antigen-binding fragments thereof, are TNFR2 antagonists, such as dominant TNFR2 antagonists. The polypeptides can be used to suppress the T-reg- or MDSC-mediated deactivation of tumor reactive T lymphocytes, expand populations of tumor-reactive cytotoxic T cells, and/or to directly kill TNFR2+ tumor cells. The antagonistic TNFR2 polypeptides described herein can be used to treat a wide variety of cancers and infectious diseases.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

84.

INTEGRIN ANTAGONISTS

      
Document Number 03112523
Status Pending
Filing Date 2019-08-08
Open to Public Date 2020-02-13
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Arnaout, M. Amin

Abstract

The present application relates to compounds which are integrin antagonists. Methods of preparing the integrin antagonists and methods of treating diseases and disorders associated with abnormal levels and/or expression of one or more integrins are also provided.

IPC Classes  ?

  • C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K 31/404 - Indoles, e.g. pindolol
  • A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
  • A61K 31/428 - Thiazoles condensed with carbocyclic rings
  • A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
  • A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
  • A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
  • A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
  • A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
  • C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
  • C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 471/04 - Ortho-condensed systems
  • C07D 495/04 - Ortho-condensed systems

85.

DELIVERY OF ENERGY TO A TARGET REGION OF A PATIENT'S BODY TO SATISFY THERAPEUTIC REQUIREMENTS PRECISELY

      
Document Number 03109130
Status In Force
Filing Date 2019-08-09
Open to Public Date 2020-02-13
Grant Date 2023-04-11
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Levin, Philip

Abstract

A system can deliver a specific amount of energy to a target region of a patient's body by scanning an energy beam over a precise path. The system can include a beam-path determination unit that defines the path and a duration for an energy beam to deliver a dose and/or a fluence of energy to the target region of the patient's body of the shape and/or the size. The system can also include an energy delivery system comprising an energy source that projects the energy beam for the duration and director device that directs (or scans) the energy beam along the path to deliver the dose and/or the fluence to the target region to achieve the dose profile and/or the fluence profile.

IPC Classes  ?

  • A61N 5/06 - Radiation therapy using light
  • A61B 18/18 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
  • A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser

86.

POLYPEPTIDE INTEGRIN ANTAGONISTS

      
Document Number 03112193
Status Pending
Filing Date 2019-08-08
Open to Public Date 2020-02-13
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Arnaout, M. Amin

Abstract

The present application relates to polypeptides which are integrin antagonists. Methods of preparing the integrin antagonists and methods of treating diseases and disorders associated with abnormal levels and/or expression of one or more integrins are also provided.

IPC Classes  ?

  • C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin (CIG)
  • A61K 49/00 - Preparations for testing in vivo
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • C07K 7/64 - Cyclic peptides containing only normal peptide links
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants

87.

ACTIVE QUADRATURE DEMODULATION FOR SUBSAMPLED/CIRCULAR RANGING OPTICAL COHERENCE TOMOGRAPHY

      
Document Number 03107927
Status Pending
Filing Date 2019-07-30
Open to Public Date 2020-02-06
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Vakoc, Benjamin J.
  • Lippok, Norman

Abstract

A method including: scanning a sample over a period of time using an electro-magnetic radiation source, the period of time including a first time period and a second time period, a sample portion of the electro-magnetic radiation source being directed to the sample in a sample arm of an optical interferometric system, and a reference portion of the electro-magnetic radiation source being directed to a reference arm of the optical interferometric system; applying, using a phase modulator, a phase shift comprising a first phase shift and a second phase shift to at least one of the reference portion or the sample portion of the electro-magnetic radiation source, the first phase shift being applied during the first time period and the second phase shift being applied during the second time period, the second phase shift having a difference of 90 degrees from the first phase shift; acquiring in-phase data based on a first interference between first backscattered electro-magnetic radiation during the first time period and the at least one of the reference portion or the sample portion subjected to the first phase shift; acquiring quadrature data based on a second interference between second backscattered electro-magnetic radiation during the second time period and the at least one of the reference portion or the sample portion subjected to the second phase shift; and determining a complex interference signal based on the in-phase data and the quadrature data.

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • G01J 3/00 - Spectrometry; Spectrophotometry; Monochromators; Measuring colours
  • G01J 3/28 - Investigating the spectrum
  • G01N 21/00 - Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
  • G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
  • G01N 21/47 - Scattering, i.e. diffuse reflection

88.

ANTIBODY TUMOR-TARGETING ASSEMBLY COMPLEXES

      
Document Number 03104185
Status Pending
Filing Date 2019-07-02
Open to Public Date 2020-01-09
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Cobbold, Mark
  • Millar, David

Abstract

The present disclosure provides antibody tumor-targeting assembly complexes (ATTACs) for selectively activating desired immune cells in the tumor microenvironment.

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61P 35/00 - Antineoplastic agents
  • C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

89.

POWDERED FORMULATIONS OF CROMOLYN SODIUM AND .ALPHA.-LACTOSE

      
Document Number 03105392
Status Pending
Filing Date 2019-07-02
Open to Public Date 2020-01-09
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • AZTHERAPIES, INC. (USA)
Inventor
  • Elmaleh, David R.
  • Gonzalez, Juan B.

Abstract

The present disclosure is directed to a composition comprising micronized cromolyn sodium, a-lactose, and a salt of fatty acid, wherein the a-lactose has a particle size distribution of D90 of 45-70 µm, D50 of 10-35 µm, and D10 of 2-13 µm. The present disclosure is also directed to a method of treating Alzheimer's disease, amyloidosis-associated condition (AAC), traumatic brain injury, Huntington's disease, atherosclerosis, cytokine release syndrome (CRS), dementia, head injury, infection, neuroinflammation, prion disease, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease, or asthma using the composition.

IPC Classes  ?

  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A61K 9/14 - Particulate form, e.g. powders
  • A61K 9/72 - Medicinal preparations characterised by special physical form for smoking or inhaling
  • A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
  • A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

90.

CHIMERIC ANTIGEN RECEPTORS TARGETING CD37 AND CD19

      
Document Number 03099928
Status Pending
Filing Date 2019-06-21
Open to Public Date 2019-12-26
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Maus, Marcela V.

Abstract

The invention provides bispecific chimeric antigen receptors (CARs) targeting CD37 and CD19, as well as related molecules, immune cells including the same, compositions thereof, and their methods of use. The invention further provides methods for treating a disease or disorder, e.g., a cancer.

IPC Classes  ?

  • C07K 19/00 - Hybrid peptides
  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • A61K 35/14 - Blood; Artificial blood
  • A61P 35/00 - Antineoplastic agents
  • A61P 35/02 - Antineoplastic agents specific for leukemia
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 15/62 - DNA sequences coding for fusion proteins

91.

METHODS AND COMPOSITIONS FOR CHIMERIC ANTIGEN RECEPTOR TARGETING CANCER CELLS

      
Document Number 03103130
Status Pending
Filing Date 2019-05-24
Open to Public Date 2019-12-19
Owner
  • THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Dotti, Gianpietro
  • Ferrone, Soldano
  • Hudson, Hannah Reid
  • Dukhovlinova, Elena
  • Ferrone, Cristina
  • Wang, Xinhui

Abstract

The present invention provides a chimeric antigen receptor (CAR) that recognizes CSPG4 as well as methods of use in the treatment of diseases and disorders.

IPC Classes  ?

  • C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
  • C12N 5/078 - Cells from blood or from the immune system
  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • A61P 35/00 - Antineoplastic agents
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
  • G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

92.

GENE THERAPY FOR ALZHEIMER'S DISEASE

      
Document Number 03100946
Status Pending
Filing Date 2019-05-22
Open to Public Date 2019-11-28
Owner
  • THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Shen, Jie
  • Kelleher Iii, Raymond J.

Abstract

The present disclosure provides, among other things, methods for using presenilin based gene therapy to treat neurodegenerative dementia including, but not limited to Alzheimers disease, frontotemporal dementia, frontotemporal lobar degeneration, Picks disease, Lewy body dementia, memory loss, and cognitive impairment including mild cognitive impairment (MCI).

IPC Classes  ?

  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • A61K 35/76 - Viruses; Subviral particles; Bacteriophages
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
  • C12N 15/12 - Genes encoding animal proteins
  • C12N 15/86 - Viral vectors

93.

ADDITIVE MANUFACTURE OF COMPLEX IMPLANTABLE LIVING DEVICES

      
Document Number 03100894
Status Pending
Filing Date 2019-05-28
Open to Public Date 2019-11-28
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Vacanti, Joseph P.
  • Hancock, Matthew J.
  • Oliver, Mark S.
  • Spann, Andrew P.

Abstract

A cell-scaffold device includes at least one channel network including an inlet, a plurality of channels include a parent channel having an end portion communicating with the inlet and another end portion communicating with a first bifurcation, forming two child channels. Each child channel has an end portion communicating with a respective end portion of the first bifurcation and another end portion communicating with a second bifurcation, forming two grand-child channels from each child channel. Each grand-child channel has an end portion communicating with a respective end portion of the second bifurcation and another end portion. The other end portion of the grand-child channel either forms an outlet or a third child channel in communication with the grand-child channel. Each forming of grand-child channels defines a generation of the fractal structure. The devices are of use as scaffolds for seeding, growing, and maintaining cells implanted in and/or on the device.

IPC Classes  ?

  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61F 2/02 - Prostheses implantable into the body
  • B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
  • C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
  • C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

94.

CCCTC-BINDING FACTOR VARIANTS

      
Document Number 03100726
Status Pending
Filing Date 2019-05-17
Open to Public Date 2019-11-21
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Cottman, Rebecca Tayler
  • Joung, J. Keith

Abstract

The present invention relates to an engineered CCCTC-binding factor (CTCF) variant including at least one amino acid residue in at least one zinc finger that differs in sequence from the amino acid sequence of a wild-type CTCF, where the engineered CTCF variant binds to a mutant CTCF binding sequence (CBS) with a higher affinity than wild-type CTCF, the mutant CBS including at least one nucleotide base that differs in sequence from the nucleotide sequence of a consensus CBS, where the at least one amino acid residue that differs in sequence from the amino acid sequence of a wild-type CTCF is selected from the group consisting of the amino acid residues at the position(s) -1, +1, +2, +3, +5, and +6 of any of ZF7, ZF6, ZF5, ZF4, and ZF3 of the engineered CTCF variant.

IPC Classes  ?

  • A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K 19/00 - Hybrid peptides
  • C12N 15/09 - Recombinant DNA-technology

95.

METHODS OF MODULATING ANTIGENICITY TO ENHANCE RECOGNITION BY T-CELLS

      
Document Number 03098320
Status Pending
Filing Date 2019-05-16
Open to Public Date 2019-11-21
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Cobbold, Mark
  • Benes, Cyril
  • Shi, Feng

Abstract

The present invention provides methods and compositions for increasing tumor antigenicity by increasing the level of expression of phosphoneoantigens in cells (e.g., restoring the expression of a phosphoneoantigen on the surface of a cancer cell). The invention also provides methods and compositions for enhancing recognition of phosphoneoantigens by immune cells.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

96.

SENSITIVE IN VITRO ASSAYS FOR SUBSTRATE PREFERENCES AND SITES OF NUCLEIC ACID BINDING, MODIFYING, AND CLEAVING AGENTS

      
Document Number 03097044
Status Pending
Filing Date 2019-04-17
Open to Public Date 2019-10-24
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Joung, J. Keith
  • Pattanayak, Vikram
  • Petri, Karl
  • Gehrke, Jason Michael
  • Sasaki, Kanae Esther

Abstract

Methods and compositions for performing highly sensitive in vitro assays to define substrate preferences and off-target sites of nucleic-acid binding, modifying, and cleaving agents.

IPC Classes  ?

  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
  • C12Q 1/6844 - Nucleic acid amplification reactions
  • C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
  • C40B 10/00 - Directed molecular evolution of macromolecules, e.g. RNA, DNA or proteins
  • C40B 30/00 - Methods of screening libraries
  • C12N 9/22 - Ribonucleases

97.

ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER

      
Document Number 03097568
Status Pending
Filing Date 2019-04-22
Open to Public Date 2019-10-24
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Elmaleh, David R.
  • Shoup, Timothy M.

Abstract

The present disclosure relates to pharmaceutical compositions including a compound derived from a parent compound having a hydroxyl or amino moiety, wherein the hydroxyl in the parent compound is presented as an ester in the compound or the amino in the parent compound is presented as an amide in the compound, and their use to prevent or treat neurological disease.

IPC Classes  ?

  • C07C 233/22 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
  • A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
  • A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
  • A61K 31/223 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-amino acids
  • A61K 31/4045 - Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
  • A61K 31/7024 - Esters of saccharides
  • A61K 49/00 - Preparations for testing in vivo
  • A61K 51/04 - Organic compounds
  • C07C 217/60 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
  • C07C 219/28 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton

98.

COMBINATION THERAPIES FOR THE TREATMENT OF AMYOTROPIC LATERAL SCLEROSIS AND RELATED DISORDERS

      
Document Number 03096545
Status Pending
Filing Date 2019-04-09
Open to Public Date 2019-10-17
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Elmaleh, David R.

Abstract

Described herein are methods of treating neuron inflammation conditions, for example, amyotropic lateral sclerosis and prion disease, comprising administering a therapeutically effective amount of a combination of cromolyn or a cromolyn derivative compound and an anti-inflammatory agent.

IPC Classes  ?

  • A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
  • A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

99.

MICROFLUIDIC SYSTEMS AND METHODS TO DENUDE MAMMALIAN OOCYTES

      
Document Number 03096048
Status Pending
Filing Date 2019-04-04
Open to Public Date 2019-10-10
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Weng, Lindong
  • Lee, Gloria Y.
  • Toner, Mehmet

Abstract

Microfluidic systems are configured to process liquid samples that include cumulus-oocyte complexes (COCs), such as raw follicular fluid, in an automated and continuous manner to produce oocytes separate or "denuded" from surrounding cumulus cells. The systems include a substrate and a channel that can have two or more sub-channels. Each channel includes an inlet, an outlet, and one or more stages arranged in series. Each of the stages includes one or more expansion units and one or more constriction units. At least one stage includes constriction units having jagged internal surfaces, e.g., teeth, that help remove the cumulus cells from the COCs.

IPC Classes  ?

  • B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
  • A61B 17/00 - Surgical instruments, devices or methods, e.g. tourniquets
  • A61D 19/00 - Instruments or methods for reproduction or fertilisation
  • A61D 19/02 - Instruments or methods for reproduction or fertilisation for artificial insemination
  • A61D 19/04 - Instruments or methods for reproduction or fertilisation for embryo transplantation
  • C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus

100.

METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR DISEASE

      
Document Number 03091274
Status Pending
Filing Date 2019-02-19
Open to Public Date 2019-08-22
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Lindsay, Mark E.
  • Cardenas, Christian Lino
  • Malhotra, Rajeev

Abstract

The technology described herein relates to methods and compositions to prevent or treat vascular disease by targeting the epigenetic regulation of gene expression of vascular smooth muscle cell cytoskeletal proteins.

IPC Classes  ?

  • C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
  • C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
  • A61P 9/00 - Drugs for disorders of the cardiovascular system
  • C12N 9/10 - Transferases (2.)
  1     2     3     4        Next Page